Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H25ClN2OS |
| Molecular Weight | 400.965 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1CCN(CC\C=C2/C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1
InChI
InChIKey=WFPIAZLQTJBIFN-BLLMUTORSA-N
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5+
trans-Clopenthixol is a typical antipsychotic drug of the thioxanthene class. Clopenthixol is composed of a mixture of cis-clopenthixol and trans-clopenthixol. The two isomers do not differ in several pharmacological properties, for instance, anti-noradrenergic effect. However, cis-clopenthixol possesses anti-dopaminergic effects, while trans-Clopenthixol not. Cis-Clopenthixol indicated for the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behavior.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. | 1986 Dec |
|
| Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. | 1991 Dec |
|
| Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. | 2004 Aug |
|
| Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia. | 2005 Jul |
|
| [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
| Fatal exertional heat stroke in a patient receiving zuclopenthixol, quetiapine and benztropine. | 2007 Fall |
|
| Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. | 2009 Nov 13 |
|
| Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. | 2010 Apr |
|
| Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. | 2012 Apr 18 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:14:51 UTC 2023 , Edited by admin on Fri Dec 15 16:14:51 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID90110026
Created by
admin on Fri Dec 15 16:14:51 UTC 2023 , Edited by admin on Fri Dec 15 16:14:51 UTC 2023
|
PRIMARY | |||
|
5372683
Created by
admin on Fri Dec 15 16:14:51 UTC 2023 , Edited by admin on Fri Dec 15 16:14:51 UTC 2023
|
PRIMARY | |||
|
C81091
Created by
admin on Fri Dec 15 16:14:51 UTC 2023 , Edited by admin on Fri Dec 15 16:14:51 UTC 2023
|
PRIMARY | |||
|
53772-84-2
Created by
admin on Fri Dec 15 16:14:51 UTC 2023 , Edited by admin on Fri Dec 15 16:14:51 UTC 2023
|
PRIMARY | |||
|
FLE878A8ZI
Created by
admin on Fri Dec 15 16:14:51 UTC 2023 , Edited by admin on Fri Dec 15 16:14:51 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
